Drugs / donor regulatory T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02385019 | Mar 2015 → Mar 2019 | graft versus host disease | Gulbenkian Institute for Molecular Medicine | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | donor regulatory T cells | “Phase 1/2 clinical study evaluating safety (Phase 1) and preliminary efficacy (Phase 2) of donor regulatory T cells for patients with steroid-refractory chronic graft versus...” NCT02385019 ↗ |
| Modality | Cell therapy | “Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease” NCT02385019 ↗ |